Alembic Ltd — Interim / Quarterly Report 2021

Aug 6, 2021

To, The Manager, Listing Department, National Stock Exchange of India Ltd Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai

Dear Sir,

Sub: Outcome of Board Meeting

With reference to the captioned subject, the exchange is hereby informed that the Board of Directors of Alembic Limited at its meeting held today has inter alia approved the Unaudited Financial Results of the Company for the quarter ended on 30" June, 2021.

We enclose herewith the following:

• 1) Consolidated Unaudited Financial Results of the Company for the quarter ended on 30* June, 2021.
• 2) Standalone Unaudited Financial Results of the Company for the quarter ended on 30% June, 2021.
• 3) Limited Review Report by Statutory Auditors on Consolidated as well as on Standalone Unaudited Financial Results.

The time of commencement of the Board Meeting was 2:30 p.m. and the time of conclusion was 3:50 p.m.

We request you to kindly take the same on your record.

Thanking you.

Yours faithfully, For Alembic Limited Company Secretary

Encl.: A/a

Statement of Consolidated Unaudited Financial Results for the Quarter ended 30th June, 2021

	Aiomiicy,	ALEMBIC LIMITED
	1©	CIN:L26100GJ1907PLCO00033	Regd.Office: Alembic Road, Vadodara 390 003
		Ph:0265 2280550 www.alembiclimited.com		Email:alembic.investors@alembic.co.in
	Statement of Consolidated Unaudited Financial Results for the Quarter ended	30th June, 2021			Rs. in Lakhs
Sr.			Quarter Ended		Year Ended
No.	Particulars	30.06.2021 (Unaudited)	31.03.2021 (Audited)	30.06.2020 (Unaudited)	31.03.2021 (Audited)
1	Revenue from Operations	2,082	2,889	1,339	7,352
2	Other Income	196	177	282	1,027
3	Total Income	2,278	3,066	1,621	8,379
4	Expenses Cost of Materials Consumed	234	405	253	1,177
	Cost of Construction Changes in Inventories of Finished Goods and WIP	248 304	1,094 (239)	0 72	1,286 (239)
	Employee Benefit Expenses Finance Costs	547	501	620	2,260
	Depreciation and amortisation expense	10 113	9 103	S 93	36 394
	Other Expenses	341	733	320	1,761
	Total Expenses	1,797	2,607	1,367	6,675
5	Profit Before Tax	481	459	254	1,704
6	Tax Expenses Current Tax	38	93	12	290
	Deferred Tax Short / (Excess) Provision of earlier years	8 -	7 (6)	31 -	35 (6)
7	Net Profit after tax for the Period	384	364	211	1,384
8	Share of Associate's Profit	4,522	6,830	8,641	32,900
9	Net Profit after tax and Share of Associate's Profit	4,906	7,194	8,852	34,284
	10 Other Comprehensive Income A (i) Items that will not be reclassified to Profit or Loss	(5,548)	27,164	3,558	38,992
	(ii) Income tax relating to items that will not be reclassified to Profit or Loss	650	(3,124)	(390)	(4,452);
	B (i) Items that will be reclassified to Profit or Loss	53	4	(8)	' (75)
	11 Total Comprehensive Income/(Loss) for the Period	62	31,238	12,011	68,749
	12 Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64
	13 Other Equity (excluding Revaluation Reserve)				1,80,277
	14 Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	1.91	2.80	3.45	13:35)

Alembic Limited

	Alembic Limited
	Segment wise Consolidated Revenue and Results		Quarter Ended		Rs. In Lakhs Year Ended
	Particulars			30.06.2021 31.03.2021 30.06.2020 31.03.2021
Sr. No. 1	Segment Revenue Revenue from Operations	(Unaudited) (Audited) (Unaudited) (Audited)
	a. Active Pharmaceutical ingredients Business	1,069	716	727	2,849
	b, Real Estate Business Total Income from Operations (Net)	1,013 2,082	2,173 2,889	612 1,339	4,502 7,352.
2	Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)
	a. Active Pharmaceutical Ingredients Business	141	(163)	(52)	(128)
	b. Real Estate Business	277	571	100	1,312
	Total	418	408	48	1,184
	Unallocable income and Expenditure
	{i) Interest Expense (ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	(10) 69	(9) (89)	(9): 151	(36) 115
	{iii) Other Income / (Expense)	4	150	63	442
	Total Profit Before Tax	481	459	254	1,704
3	Segment Assets
	a. Active Pharmaceutical Ingredients Business	15,115	15,445	15,012	15,445
	b. Real Estate Business	22,016	21,494	13,798	21,494
	c. Unallocated	2,02,840	_2,03,958	1,30,787	_2,03,958
	Total	2,40,370	2,40,896}	1,59,597}	2,40,896
4	{Segment Liabilities a. Active Pharmaceutical Ingredients Business	1,896	1,712	1,653	1,712
	b. Real Estate Business	4,661	4,819	3,504	4,819
	c. Unallocated	4,048	4,663 11,193	624	4,663

Notes:

1. The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.

2 During the quarter ended 30th June 2021, due to resurgence of Covid-19, the Real Estate segment was adversely impacted with slow: down in construction activities, new residential bookings and rental activities. The AP! segment, being a part of essential services is largely unaffected.

The Company's management has made an internal assessment and believes that the impact is likely to be short term in nature and does not foresee any medium to long term risk in company's ability to continue as a going concern.

3 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year,

For Alembic Limited

Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June, 2021

		ALEMBIC LIMITED
		CIN:L26100GJ1907PLC000033 Regd.Office: Alembic Road, Vadodara 390 003 Ph:0265 2280550
		www.alembiclimited.com		Email:alembic.investors@alembic.co.in
	Statement of Standalone Unaudited Financial Results for the Quarter ended	30th June, 2021	Quarter Ended		Rs. in Lakhs Year Ended
Sr. No,	Particulars	30.06.2021 (Unaudited)	31.03.2021 (Audited)	30.06.2020 (Unaudited)	31.03.2021 (Audited)
1	Revenue from Operations	2,039	2,854	1,310	7,230
2	Other Income	196	172	281
3					997
	Total Income	2,235	3,026	47591:	8,227
4	Expenses Cost of Materials Consumed	234	405	253	1,177
	Cost of Construction Changes in Inventories of Finished Goods and WIP	248 304	1,094 (239)	0 72	1,286 (239)
	Employee Benefit Expenses Finance Costs	547 7	501 7	620 6	2,260 27
	Depreciation and amortisation expense Other Expenses	104 319	100 705	93 296	391 1,673
	Total Expenses	1,764	2,573	1,341	6,575
5	Profit Before Tax	471	453	250	1,652
6	Tax Expenses Current Tax	88	93	12	290
	Deferred Tax	8	3	31	31:
7	Short / (Excess) Provision of earlier years Net Profit after tax for the Period	- 375	(6) 363	- 207	(6) 1,336
8	Other Comprehensive Income (i) Items that will not be reclassified to Profit or Loss	(5,392)	27,003	3,751	39,035
	(ii) Income tax relating to items that will not be reclassified to Profit or Loss	624	(3,096)	(424)	(4,458)
9	Total Comprehensive Income/(Loss) for the Period	(4,394)	24,270	3,534	35,913
	10 Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64
	11 Other Equity (excluding Revaluation Reserve)				33,256
	12 Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	0.15	0.14	0.08	0.52

Alembic Limited

	Alembic Limited
Sr. No.	Segment wise Standalone Revenue and Results		Quarter Ended		Rs. In Lakhs Year Ended
1	Particulars Segment Revenue	(Unaudited)		30.06.2024 31.03.2021 30.06.2020 31.03.2021 (Audited) (Unaudited)	(Audited)
	Revenue from Operations a. Active Pharmaceutical Ingredients Business
	b. Real Estate Business	1,069 969	716 2,138	727 582	2,849 4,381
2	Total income from Operations (Net) Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each	2,039	2,854	1,310	7,230
	segment) a. Active Pharmaceutical Ingredients Business	141	(163)	(52)	(128)
	b. Real Estate Business Total	264 406	562 399	93 42	1,250 1,122
	Unallocable Income and Expenditure {i) Interest Expense	{7)	(7)	{6}	(27)
	{ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset (iii) Other Income / (Expense)	69	(89)	151	115
	Total Profit Before Tax	4 474	i50 453	63 250	442 1,652
3	Segment Assets a. Active Pharmaceutical Ingredients Business	15,115	15,445	15,012	15,445
	b. Real Estate Business ¢. Unallocated	21,710	20,284	13,707	20,284
	Total	51,836 88,661	57,917. 93,645	28,775, 57,494	57,917 93,645
4	Segment Uabilities a. Active Pharmaceutical Ingredients Business	1,896	1,712	1,653	1,712
	b. Real Estate Business ¢. Unallocated Total	4,434 4,043	4,594 4,658	3,372 624	4,594 4,658

Notes:

¹The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.

²During the quarter ended 30st June 2021, due to resurgence of Covid-19, the Real Estate segment was adversely impacted with slow-down in construction activities, new residential bookings and rental activities. The AP! segment, being a part of essential services is largely unaffected.

The Company's management has made an internal assessment and believes that the impact is likely to be short term in nature and does not foresee any medium to long term risk in company's ability to continue as a going concern.

³The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year,

For Alembic Limited

Place : London

Chairman

Chartered Accountants

Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

• 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Alembic Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30% June, 2021 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
• 1. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
• 1. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable

• 1. The statement includes results of the following entities: i. Alembic City Limited (Subsidiary) AX /
• ii. Alembic Pharmaceuticals Limited (Associate) A.

• 1. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
• 1. We did not review the financial result of a subsidiary included in the unaudited consolidated financial results, whose financial results reflect total revenue of Rs. 165.81 lakhs, total net loss after tax of Rs. 27.08 Lakhs and total comprehensive loss of Rs. 27.14 Lakhs for the quarter ended 30* June, 2021. The unaudited consolidated financial results also include the Group's share of net profit after tax of Rs. 4,521.99 Lakhs and total comprehensive income of Rs. 4,446.43 lakhs quarter ended 30' June, 2021, as considered in the statement, in respect of an associate. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiary and associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the unaudited consolidated quarterly financial results is not modified with respect of the above matter.

For CNK & Associates LLP

Chartered Accountants Firm Registration No. 101 961W/W-100036

Alok Shah Partner Membership No. 042005 Place : Vadodara Date : 06" August, 2021 UDIN : 21042005AAAAMB9451

Chartered Accountants

CN Ka As sociates LLP C- 201 - 202, Shree Siddhi Vinayak Complex, Opp. Alkapuri Side Railway Station, Faramji Road, Alkapuri, Vadodara - 390 005. Ph. : +91-265-2343483, 2354359 Email : alok@cnkindia.com

Independent Auditor's Review Report on Unaudited Standalone Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

• 1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of Alembic Limited ("the Company") for the quarter ended 30% June, 2021 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
• 1. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
• 1. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
• 1. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the informatio red to be disclosed in terms of the

Listing Regulations, including the manner in which, it is to material misstatement. be disclosed, or that it contains any

For CNK & Associates LLP

Chartered Accountants Firm Registration No. 101961 W/W-100036

ay Alok Shah = <\ % | VADODARA } « | Partner \2 2 \% =/ Membership No. 042005 Cae Place : Vadodara Date : 06 August, 2021 UDIN : 21042005AAAAMA3254